Table 4: Vitek2 automated system (bioMérieux, Mary l'Etoile, France) antimicrobial susceptibility testing (AST) for the ten representative isolates for spa sequencing and MLST typing.

Number ISOLATE IDENTITY/GENOTYPE VITEK2 AUTOMATED SYSTEM (SYSTEM (bioMérieux, Mary l'Etoile, France) RESULT RESISTANT (R) ANTIBIOTICS
(µg/ml)		 SUSCEPTIBLE (S) ANTIBIOTICS (µg/ml) INTERMIDIATE (I) ANTIBIOTICS (µg/ml)
1 2Spa cluster A-SCCmec I-agr I-PFGE A3 MRSA Clindamycin (≥ 8), Erythromycin (≥ 8), Fusidic Acid (≥ 32), Oxacillin (≥ 4),
Rifampicin (≥ 32), Teicoplanin (≥ 32), Tetracycline (8) and Vancomycin (≥ 32)		 Ciprofloxacin (≥ 0.5), Gentamicin (≥0.5), Moxifloxacin (≥ 0.25), Tigecycline (0.5) and Trimethoprim-Sulfamethoxazole (≥10)
2 71 Spa cluster D-SCCmec IV-agr I-PFGE A3 MRSA Clindamycin (≥ 8), Erythromycin (≥ 8), Fusidic Acid (≥ 32), Gentamicin (≥ 16), Rifampicin (≥ 32), Teicoplanin (≥ 32), Tetracycline (≥ 16), Trimethoprim-Sulfamethoxazole (≥ 320), Oxacillin (≥ 4) and Vancomycin (≥ 32) Ciprofloxacin (≥ 0.5), Moxifloxacin (≥ 0.25) and Tigecycline (0.5)
3 100 Spa cluster A-SCCmec IVd-agr I-PFGE A3 MRSA Ciprofloxacin (≥ 8), Clindamycin (≥ 0.25), Erythromycin (≥ 8), Gentamicin (≥ 16), Tetracycline (≥ 16), Trimethoprim-Sulfamethoxazole (≥ 320), Oxacillin (≥ 4) and Rifampicin (≥ 32) Fusidic Acid (≥ 0.5), Linezolid (1), Moxifloxacin (1), Mupirocin (≥ 2), Teicoplanin (≥ 0.5), Tigecycline (≥ 0.12) and Vancomycin (1)
4 131 SCCmec IVd-agr I-PFGE A MRSA Ciprofloxacin (≥ 8), Clindamycin (≥ 0.25), Erythromycin (≥ 8), Gentamicin (≥ 16), Moxifloxacin (2), Oxacillin (≥ 4), Tetracycline (≥ 16) and Trimethoprim-Sulfamethoxazole (≥ 320) Fusidic Acid (≥ 0.25), Linezolid (2), Rifampicin (≥ 0.5), Teicoplanin (≥ 0.5), Tigecycline (0.25) and Vancomycin (2)
5 133 SCCmec IVa-agr I-PFGE A MRSA Ciprofloxacin (≥ 8), Clindamycin (≥ 0.25), Erythromycin (≥ 8), Gentamicin (≥ 16), Oxacillin (≥ 4), Tetracycline (≥ 16) and Trimethoprim-Sulfamethoxazole (≥ 320) Fusidic Acid (≥ 0.5), Linezolid (2), Moxifloxacin (1), Rifampicin (≥ 0.5), Teicoplanin (≥ 0.5), Tigecycline (0.25) and Vancomycin (≥ 0.5)
6 134
SCCmec IVd-agr I-PFGE B2		 MRSA Clindamycin (≥ 0.25), Erythromycin (≥ 8) , Gentamicin (≥ 16), Oxacillin (≥ 4), Tetracycline (≥ 4) and Trimethoprim-Sulfamethoxazole (80) Ciprofloxacin (≥ 0.5), Fusidic Acid (≥ 0.5), Linezolid (1), Moxifloxacin (≥ 0.25), Mupirocin (≥2), Teicoplanin (2), Tigecycline (0.25) and Vancomycin (2)
7 143
Spa cluster A-SCCmec IVa-agr-III-PFGE B		 MRSA Ciprofloxacin (≥ 8), Clindamycin (≥ 0.25), Erythromycin (≥ 8), Gentamicin (≥ 16), Oxacillin(≥ 4) , Rifampicin (≥ 32), Tetracycline (≥ 16) and Trimethoprim-Sulfamethoxazole (≥ 320) Fusidic Acid (≥ 0.5), Linezolid (2), Moxifloxacin (≥ 2) , Mupirocin (≥ 2), Teicoplanin (≥ 0.5), Tigecycline (≥ 0.12) and Vancomycin (≥ 0.5)
8 165
Not typed 		MRSA Clindamycin (≥ 0.25), Erythromycin (≥ 8), Gentamicin (≥ 16), Oxacillin (≥ 4), Rifampicin (≥ 32), Tetracycline (2) and Trimethoprim-Sulfamethoxazole (160) Linezolid (1), Moxifloxacin (0.5),Teicoplanin (8), Tigecycline (≥ 0.12) and Vancomycin (2) Ciprofloxacin (2) and Fusidic Acid (4)
9 183 Spa cluster I-SCCmec II-agr I, III-PFGE J MRSA Ciprofloxacin (≥ 8), Clindamycin (≥ 8), Erythromycin (≥ 8) , Moxifloxacin (≥ 8) and Oxacillin (≥ 8) Fusidic Acid (≥ 0.25) , Gentamicin (≥ 0.5), Linezolid (≥ 8), Tetracycline (≥ 1), Teicoplanin (2), Tigecycline (≥ 0.5), Rifampicin (≥ 0.5) and Vancomycin (≥ 0.5)